Carboranyl amino acids for site specific neutron capture therapy of malignant melanoma
Technical Report
·
OSTI ID:5266146
The single most difficult problem yet to be solved for effective clinical use of boron neutron capture therapy (BNCT) in the United States is the development of highly tumor-selective third generation boron compounds. In this context, the boronated amino acids and peptides would be a significant step toward this goal. Our preliminary in vitro finding that carboranylalanine is a highly potent neutron sensitizer strongly suggests that this amino acid is a most desirable third generation compound, and our development of both chiral and achiral synthesis for its production are a necessary prerequisite for advancement of the field in this area. We further believe that insertion of this amino acid into carefully selected peptides will provide substances able to a target a much wider variety of malignancies than just melanoma. It seems clear that further investigations into this promising field are warranted if BNCT is to achieve clinical acceptability.
- Research Organization:
- California Univ., San Francisco, CA (United States)
- Sponsoring Organization:
- DOE; USDOE, Washington, DC (United States)
- DOE Contract Number:
- FG03-89ER60873
- OSTI ID:
- 5266146
- Report Number(s):
- DOE/ER/60873-T2; ON: DE92013811
- Country of Publication:
- United States
- Language:
- English
Similar Records
Carboranyl amino acids for site specific neutron capture therapy of malignant melanoma
Carboranyl amino acids for the specific neutron capture therapy of malignant melanoma
Strategies for the design and synthesis of boronated nucleic acid and protein components as potential delivery agents for neutron capture therapy
Technical Report
·
Mon Dec 30 23:00:00 EST 1991
·
OSTI ID:10145813
Carboranyl amino acids for the specific neutron capture therapy of malignant melanoma
Technical Report
·
Mon Jan 14 23:00:00 EST 1991
·
OSTI ID:5391334
Strategies for the design and synthesis of boronated nucleic acid and protein components as potential delivery agents for neutron capture therapy
Journal Article
·
Tue Mar 29 23:00:00 EST 1994
· International Journal of Radiation Oncology, Biology and Physics; (United States)
·
OSTI ID:6768213
Related Subjects
37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CHEMISTRY
400201 -- Chemical & Physicochemical Properties
550603* -- Medicine-- External Radiation in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
ALANINES
AMINO ACIDS
BIOASSAY
BORON COMPOUNDS
CARBON 13
CARBON COMPOUNDS
CARBON ISOTOPES
CARBORANES
CARBOXYLIC ACIDS
COMPARATIVE EVALUATIONS
DISEASES
DOCUMENT TYPES
EVALUATION
EVEN-ODD NUCLEI
ISOTOPES
LIGHT NUCLEI
MAGNETIC RESONANCE
MEDICINE
MELANOMAS
NEOPLASMS
NEUTRON CAPTURE THERAPY
NEUTRON THERAPY
NUCLEAR MAGNETIC RESONANCE
NUCLEAR MEDICINE
NUCLEI
ORGANIC ACIDS
ORGANIC BORON COMPOUNDS
ORGANIC COMPOUNDS
PROGRESS REPORT
RADIOLOGY
RADIOTHERAPY
RESONANCE
STABLE ISOTOPES
THERAPY
400201 -- Chemical & Physicochemical Properties
550603* -- Medicine-- External Radiation in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
ALANINES
AMINO ACIDS
BIOASSAY
BORON COMPOUNDS
CARBON 13
CARBON COMPOUNDS
CARBON ISOTOPES
CARBORANES
CARBOXYLIC ACIDS
COMPARATIVE EVALUATIONS
DISEASES
DOCUMENT TYPES
EVALUATION
EVEN-ODD NUCLEI
ISOTOPES
LIGHT NUCLEI
MAGNETIC RESONANCE
MEDICINE
MELANOMAS
NEOPLASMS
NEUTRON CAPTURE THERAPY
NEUTRON THERAPY
NUCLEAR MAGNETIC RESONANCE
NUCLEAR MEDICINE
NUCLEI
ORGANIC ACIDS
ORGANIC BORON COMPOUNDS
ORGANIC COMPOUNDS
PROGRESS REPORT
RADIOLOGY
RADIOTHERAPY
RESONANCE
STABLE ISOTOPES
THERAPY